Busulfanum

T-Cell Non-Hodgkin Lymphoma

Sichuan UniversitySmall moleculePhase 3Active

BB

68/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 57/ 100
Competitive Position: 89/ 100

Competitive context

83 Active assets in the T-Cell Non-Hodgkin Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Fludarabine GC Cell Corporation	Phase 2	BBB
Brentuximab Vedotin Yale University	Phase 4	BBB
Lenalidomide Samsung Medical Center	Phase 2	BB
Cyclophosphamide GC Cell Corporation	Phase 3	BB
Rituximab Memorial Sloan Kettering Cancer Center	Phase 2	BB

View all 50 →

Same molecule, other indications

Busulfanum is also rated in:

myelodysplastic/myeloproliferative neoplasmActive

BBB

Indicative · Phase 2/3

76 / 100

graft versus host diseaseActive

BBB

Indicative · Phase 4

74 / 100

disease related to hematopoietic stem cell transplantActive

BBB

Indicative · Phase 3

74 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.